Sanofi Investing Activities - Other 2010-2024 | SNY
Sanofi annual/quarterly investing activities - other history and growth rate from 2010 to 2024. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- Sanofi investing activities - other for the quarter ending December 31, 2024 was $-0.043B, a 82.54% decline year-over-year.
- Sanofi investing activities - other for the twelve months ending December 31, 2024 was $-0.087B, a 81.87% decline year-over-year.
- Sanofi annual investing activities - other for 2024 was $-0.043B, a 82.54% decline from 2023.
- Sanofi annual investing activities - other for 2023 was $-0.248B, a 1370.2% increase from 2022.
- Sanofi annual investing activities - other for 2022 was $-0.017B, a 0% decline from 2021.
Sanofi Annual Investing Activities - Other
(Millions of US $) |
| 2024 |
$-43 |
| 2023 |
$-248 |
| 2022 |
$-17 |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$435 |
| 2010 |
$-276 |
| 2009 |
$-33 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
